Search

KR-102962530-B1 - Antiviral pyrazolopyridinone compounds

KR102962530B1KR 102962530 B1KR102962530 B1KR 102962530B1KR-102962530-B1

Abstract

The present invention provides a compound of formula (I) as described herein (along with a pharmaceutically acceptable salt), a pharmaceutical composition comprising such compound, and a method of using such compound, salt, and composition to treat a viral infection, particularly an infection caused by a herpes virus: .

Inventors

  • 콘스트, 제프
  • 코키, 브리튼, 케이.
  • 메토보, 사우엘, 이.
  • 루, 이핀
  • 모로, 로버트, 조셉
  • 라자파크사, 나오미, 사마다라
  • 션-낸스, 갈렌
  • 튤리, 데이비드, 찰스
  • 터너, 마이클, 로버트
  • 영, 조셉, 마이클
  • 자오, 첸

Assignees

  • 노파르티스 아게
  • 길리애드 사이언시즈, 인코포레이티드

Dates

Publication Date
20260512
Application Date
20200924
Priority Date
20190926

Claims (20)

  1. Compound of formula (I) or a pharmaceutically acceptable salt thereof: In the above formula, X is , , , a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S as ring members, a 5- to 6-membered heterocycloalkyl comprising 1 to 4 ring members independently selected from N, NH, NR 17 , O, or S, or a 5- to 6-membered heterocyclil comprising 1 to 4 ring members independently selected from N, NH, NR 17 , O, or S; Y is combined, , , -O- or is, Here, * of Y represents the attachment point for X, and ** of Y represents the attachment point for R B ; q is 0 and; L MC does not exist, Z is W, and A is R 4 ; R B is phenyl, pyridinyl, thiophenyl, pyrimidinyl, or a 5- to 8-membered cycloalkyl, wherein R B is optionally substituted with 1 to 3 R 5 groups; R1 is selected from H, C1 - C3 alkyl, and C1 - C3 alkyl substituted with 1 to 3 -OH groups; R2 is selected from H, C1 - C3 alkyl, and C1 - C3 alkyl substituted with 1 to 3 -OH groups; R1 and R2 can form a ternary to hexavalent cycloalkyl ring together with the carbon to which they are attached; t is 0, 1, or 2, and; Each R3 is a cyclic substituent to which -LZ is directly attached, where present, and each R3 is independently selected from halo, CN, C1 - C3 alkoxy, C1 - C3 alkyl, C(=O)OR 10 and C(=O)NR 13 R 14 ; R4 is a C1-C3 alkyl substituted with one or two groups independently selected from H, C1- C3 alkyl , C3 - C6 cycloalkyl, -( CH2 ) 2O ( CH2 ) 2Br , or -OH, -C(=O) R15 and R10 ; Each R5 is independently selected from halo, -CN, hydroxy, -NR 13 R 14 , C 3- C 6 cycloalkyl, C 1- C 3 alkoxy, C 1- C 3 haloalkyl, and C 1 -C 3 alkyl optionally substituted with 1 to 3 R6 groups, wherein R B is substituted with 2 R5s , and each R5 is a C 1- C 3 alkyl optionally substituted with 1 to 3 R6 groups, and when directly attached to the same carbon atom, both can form a ternary to pentary cycloalkyl ring optionally substituted with 1 to 3 R6 groups together with the carbon to which they are directly attached; Each R6 is independently selected from halo, hydroxy, CN, C1 - C3 alkoxy, C1 - C3 alkyl, and C3 - C5 cycloalkyl, or Both of the two R6 groups, together with the carbon atom to which they are directly attached, can form a ternary to pentary cycloalkyl ring, or a quaternary to 6-membered heterocyclic ring comprising O, N, or S as ring members and optionally substituted with one or two groups independently selected from oxo and C1 - C3 alkyl; L is a C1 - C4 straight-chain or branched-chain alkylene linker, or L is a C1 - C4 straight-chain or branched-chain alkylene linker, or may be a linker where W is an optionally substituted ring; W is H, -OH, -OR 10 , -C(=O)NR 13 R 14 , -C(=O)OR 13 , -NR 13 R 14 , -NR 13 C(=O)OR 10 , -NR 13 C(=O)R 10 , -SO 2 R 10 , -SO 2 NR 13 R 14 , -NR 13 SO 2 R 10 , -P(=O)(OR 13 ) 2 , -S(=O)R 10 , -S(=O)(=NR 13 )R 10 , -CR 11 R 12 C(=O)NR 13 R 14 , -CR 11 R 12 C(=O)OR 13 , -CR 11 R 12 NR 13 R 14 , -CR 11 R 12 NR 13 C(=O)OR 10 , -CR 11 R 12 NR 13 C(=O)R 10 , -CR 11 R 12 SO 2 R 10 , -CR 11 R 12 SO 2 NR 13 R 14 , -CR 11 R 12 NR 13 SO 2 R 10 , -CR 11 R 12 P(=O)(OR 13 ) 2 , -CR 11 R 12 S(=O)R 10 , -CR 11 R 12 S(=O)(=NR 13 )R 10 , ternary to hexavalent cycloalkyl, phenyl, N, NH, NR 17 , pentary to hexavalent heterocycloalkyl comprising 1 or 2 ring members independently selected from O or S, N, NH, NR 17 , O or a 5- to 6-membered heterocyclile comprising 1 or 2 ring members independently selected from S, or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from N, O and S as ring members optionally fused to phenyl, and Here, the ternary to hexavalent cycloalkyl, phenyl, pentary to hexavalent heterocycloalkyl, pentary to hexavalent heterocyclyl, and pentary heteroaryl of W are respectively C1 - C3 alkyl, oxo, halo, C1 - C3 haloalkyl, -OH, -OR 10 , -OC(=O)NR 13 R 14 , -SO2 R 10, -SO2 NR 14 R 10, -SO2 NR 13 R 14 , -SO2 N = CR 13 NR 13 R 14 , -SO2 NR 13 C(=O)R 10 , -C (=O)NR 13 SO2 R 10 , -S(=O)R 10 , -S(=O ) (=NR 13 )R 10 , -NR 13 SO Optionally substituted with 1 to 3 groups independently selected from 2 NR 13 R 14 , -NR 13 SO 2 R 10 , -NR 13 R 14 , -NR 13 C(=O)R 13 , -NR 13 C(=O)OR 10 , -C(=O)NR 13 R 14 and -C(=O)OR 13 ; R 10 is selected from C 1- C 5 alkyl, C 1- C 3 haloalkyl, ternary to 6-membered cycloalkyl, phenyl, 5- to 6-membered heteroaryls having 1 to 4 heteroatoms independently selected from N, O, and S as ring members, 4- to 6-membered heterocycloalkyls comprising 1 or 2 ring members independently selected from N, NH, NR 17 , O, or S, and 4- to 6-membered heterocyclies comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O, or S, and Here, each R 10 represents C 1- C 4 alkyl, deuterium, C 1- C 4 haloalkoxy, -OH, -CN, -OC(=O)R 14 , -L 3 OR 13 , C 1- C 2 haloalkyl, oxo, -halo, -C 1- C 3 alkoxy, -OC(=O)NR 13 R 14 , -SO 2 R 13 , -SO 2 NR 13 R 14 , -SO 2 NR 13 C(=O)R 13 , -C(=O)NR 13 SO 2 R 13 , -S(=O)R 13 , -S(=O)(=NR 14 )R 13 , -NR 13 SO 2 NR 13 R 14 , -NR 13 SO 2 R 13 , -NR 13 R 14 , -NR 14 C(=O)R 13 , -NR 14 C(=O)OR 13 , -C(=O)NR 13 R 14 , -C(=O)OR 13 , -(4- to 7-membered heterocycloalkyl comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O, or S), -(4- to 7-membered heterocycloyl comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O, or S), -C 3- C 5- membered cycloalkyl and -(5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms comprising 1 to 4 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom as ring members), optionally substituted with 1 to 5 groups independently selected from C 1- C The 4- alkyl, 4- to 7-membered heterocycloalkyl, 4- to 7-membered heterocyclyl, C3 - C5 - cycloalkyl and 5- to 6-membered heteroaryl rings are each optionally further substituted with 1 to 3 groups independently selected from halo, C1 -C3 - alkyl, C1 - C3 -haloalkyl, -OR13 , -CN, and -NR13R14 ; R 11 and R 12 are each independently selected from H and C 1- C 4 alkyls; Each R 13 is independently selected from quaternary to hyphae heterocycloalkyl comprising 1 to 2 ring members independently selected from H, C 1- C 4 alkyl, N, NH, NR 17 , O, or S, quaternary to hyphae heterocyclyl comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O, or S, and C 3- C 6 cycloalkyl, wherein the C 1- C 4 alkyl, heterocyclyl, and C 3- C 6 cycloalkyl are optionally substituted with 1 to 3 groups independently selected from C 1- C 4 alkyl, halo, -OH, -NR 15 R 16 , -C(=O)OR 15 , C 1- C 2 alkoxy, and C 1- C 4 alkyl substituted with 1 to 2 hydroxyl groups; R 14 is selected from H, C 1- C 4 alkyl and C 3- C 6 cycloalkyl, wherein C 1- C 4 alkyl and C 3- C 6 cycloalkyl are optionally substituted with 1 to 3 groups independently selected from C 1- C 4 alkyl, halo, -OH, -NR 15 R 16 , C 1- C 2 alkoxy, and C 1- C 4 alkyl substituted with 1 to 2 hydroxyl groups; R 13 and R 14 , together with a directly attached nitrogen atom, may optionally include additional N, O, or S as ring members and form a quaternary to hexamembered ring optionally substituted with 1 to 3 groups selected from C 1- C 2 alkyl, C 1- C 2 alkoxy, oxo, and hydroxy; R 15 and R 16 are each independently selected from H and C 1- C 4 alkyls; Each R 17 is independently selected from H, C 1- C 4 alkyl and C 3 -C 8 cycloalkyl, or R17 is a C1 - C4 alkyl capable of forming a 5- to 8-membered ring fused to the pyrazole ring together with the nitrogen atom to which it is directly attached and the nitrogen atom of the pyrazole ring; L3 is a bonded, straight-chain, or branched-chain C1 - C3 alkylene; ' ' indicates a single or double bond.
  2. In claim 1, a compound having the structure of formula (II) or a pharmaceutically acceptable salt thereof: In the above formula, W, L, R1 , R2 , R3 , R4 , and RB are as defined in claim 1.
  3. In paragraph 1 or 2, R B is phenyl, pyridinyl, thiophenyl, or a 5- to 8-membered cycloalkyl, wherein R B is optionally substituted with 1 to 3 R 5 groups; R1 is selected from H, C1 - C3 alkyl, and C1 - C3 alkyl substituted with 1 to 3 -OH groups; R 2 is H and; t is 0, 1, or 2, and; Each R3 is a cyclic substituent to which -LW is directly attached, where present, and each R3 is independently selected from C1 - C3 alkyl; R4 is a C1-C3 alkyl substituted with one or two groups independently selected from H, C1- C3 alkyl , C3 - C6 cycloalkyl, -( CH2 ) 2O ( CH2 ) 2Br , or -OH, -C(=O) R15 and R10 ; Each R5 is independently selected from halo, -CN, C1 - C3 alkoxy, and C1 - C3 alkyl; L is a C1 - C4 straight-chain or branched-chain alkylene linker, or L is a C1 - C4 straight-chain or branched-chain alkylene linker, or may be a linker where W is an optionally substituted ring; W is a ternary to hexavalent cycloalkyl, wherein the ternary to hexavalent cycloalkyl is substituted with 1 to 3 groups independently selected from -SO₂R₁₀ , -SO₂NR₁₄R₁₀ , -SO₂NR₁₃R₁₄ , and -SO₂N = CR₁₃NR₁₃R₁₄ ; R 10 is selected from C 1- C 5 alkyl, C 1- C 3 haloalkyl, ternary to 6-membered cycloalkyl, 5-membered to 6-membered heteroaryls having 1 to 4 heteroatoms independently selected from N, O and S as ring members, 4-membered to 6-membered heterocycloalkyls comprising 1 or 2 ring members independently selected from N, NH, NR 17 , O or S, and 4-membered to 6-membered heterocyclies comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O or S, and Here, each R 10 is optionally a C 1- C 4 alkyl, deuterium, C 1- C 4 haloalkoxy, -OH, -CN, -OC(=O)R 14 , -L 3 OR 13 , -NR 13 R 14 , -NR 14 C(=O)R 13 , -NR 14 C (=O)OR 13 , -C(=O)NR 13 R 14 , -C(=O)OR 13 , (quaternary to hyphal heterocycloalkyl comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O or S), (quaternary to hyphal heterocyclyl comprising 1 to 2 ring members independently selected from N, NH, NR 17, O or S), and 1 to 5 groups independently selected from -C 3- C 5 cycloalkyl. Substituted, wherein C1 - C4 alkyl, quaternary to hyphenous heterocycloalkyl, quaternary to hyphenous heterocyclyl, and C3 - C5 cycloalkyl are each optionally further substituted with 1 to 3 groups independently selected from halo, -OR 13 and -NR 13 R 14 ; R 11 and R 12 are each independently selected from H and C 1- C 4 alkyls; Each R 13 is independently selected from quaternary to hyphae heterocycloalkyl comprising 1 to 2 ring members independently selected from H, C 1- C 4 alkyl, N, NH, NR 17 , O, or S, quaternary to hyphae heterocyclyl comprising 1 to 2 ring members independently selected from N, NH, NR 17 , O, or S, and C 3- C 6 cycloalkyl, wherein the C 1- C 4 alkyl, heterocyclyl, and C 3- C 6 cycloalkyl are optionally substituted with 1 to 3 groups independently selected from C 1- C 4 alkyl, halo, -OH, -NR 15 R 16 , -C(=O)OR 15 , C 1- C 2 alkoxy, and C 1- C 4 alkyl substituted with 1 to 2 hydroxyl groups; R 14 is selected from H and C 1- C 4 alkyls; R 15 and R 16 are each independently selected from H and C 1- C 4 alkyls; L3 is a bonded, straight-chain, or branched-chain C1 - C3 alkylene; ' ' is a compound that exhibits a single or double bond.
  4. In claim 1, a compound having the structure of formula (IIIa), formula (IIIb) or formula (IIIc) or a pharmaceutically acceptable salt thereof: (IIIa), (IIIb), (IIIc).
  5. In any one of paragraphs 1, 2 and 4, the part WL- is , , , , , , , , , , and A compound selected from.
  6. In claim 1, a compound having the structure of formula (Va) or a pharmaceutically acceptable salt thereof: (Va).
  7. In any one of paragraphs 1, 2, 4 and 6, R1 is H, methyl, or methyl substituted with one -OH group; Each R 5 is independently selected from Cl, F, and -CN; L is bonded to CH2 or CH2CH2 ; R 10 is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, cyclopropyl, cyclobutyl, pyridinyl, pyrazolyl, isoxazolyl, oxetanil, tetrahydrofuranil, tetrahydropyranil, morpholinil, piperidinyl, piperazinyl, pyrrolidinyl, and azetidinyl, Here, each R 10 represents methyl, ethyl, deuterium, -OCH 3 , -OH, -OCHF 2 , -CN, -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NHR 13 , -NHCH(=O), -NHC(=O)CH 3 , -NHC(=O)OCH 3 , -NHC(=O)CH 2 NH 2 , -NHC(=O)CH 2 N(CH 3 ) 2 , -NHC(=O)CH(CH 3 )NH 2 , -NHC(=O)C(CH 3 ) 2 NH 2 , -OCH 2 CH 2 OH, -OCH 2 CH(CH 3 ) OH, -OCH 2 CH(CH 3 ) 2 OH, -OCH(F)CH 2 OH, -OCF 2 CH 2 OH, -OCH2CH2NH2 , -OCH2CH ( CH3 ) NH2 , -OCH2C ( CH3 ) 2NH2 , -OCH2CH2NHCH3, -OCH2CH2N ( CH3 ) 2 , -OCH ( F ) CH2NH2 , -OCF2CH2NH2, -CH2OCH2CH2NH2, -CH2CH2OH , -CH2OH , -CH2NH2 , -O - Azetidinyl , -C (= O ) NH2 , -C(=O) NHCH3 , -OC(=O ) CH3 , cyclopropyl , azetidinyl , pyrrolidinyl , morpholinyl, 6-oxa- 3 - azabicyclo[3.1.1]heptanyl, Optionally substituted with 1 to 4 groups independently selected from 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, and 4,5-dihydroisoxazolyl, and Herein, methyl, ethyl, cyclopropyl, azatidinyl, pyrrolidinyl, morpholinyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl and 4,5-dihydroisoxazolyl are each compounds or pharmaceutically acceptable salts thereof optionally further substituted with one to three groups independently selected from F, -OH, -OCH3 , and -NH2 .
  8. In any one of paragraphs 1, 2, 4 and 6, R 10 is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and A compound selected from or a pharmaceutically acceptable salt thereof.
  9. In any one of paragraphs 1, 2, 4 and 6, R1 is a compound or a pharmaceutically acceptable salt thereof in which H is present.
  10. In any one of paragraphs 1, 2, 4 and 6, each R 5 is independently a compound selected from Cl, F, -CN, -OCH 3 and methyl or a pharmaceutically acceptable salt thereof.
  11. In any one of paragraphs 1, 2, 4 and 6, each R 5 is independently a compound selected from Cl and -CN or a pharmaceutically acceptable salt thereof.
  12. In any one of paragraphs 1, 2, 4 and 6 , L is a compound that is -CH₂- or -CH₂CH₂- or a pharmaceutically acceptable salt thereof.
  13. In any one of paragraphs 1, 2, 4 and 6, L is a compound that is -CH₂- or a pharmaceutically acceptable salt thereof.
  14. A compound selected from the following or a pharmaceutically acceptable salt thereof: .
  15. In paragraph 1, A compound selected from or a pharmaceutically acceptable salt thereof.
  16. A pharmaceutical composition for use in a method for treating a herpes virus infection, comprising a compound of any one of claims 1, 2, 4, 6, 14 and 15, wherein the method comprises administering said pharmaceutical composition to a patient suffering from a herpes virus infection.
  17. A pharmaceutical composition according to claim 16, wherein the herpes virus is selected from cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), herpes simplex virus including HSV-1 and HSV-2, herpes virus 6, human herpes virus 7, and Kaposi's sarcoma-associated herpesvirus.
  18. A pharmaceutical composition according to claim 16, wherein the method comprises treating a disorder induced, aggravated, or accelerated by a herpes virus infection, selected from the group consisting of Alzheimer's disease, chronic fatigue syndrome (CFS), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), inflammatory bowel disease (IBD), celiac disease, and type 1 diabetes.
  19. A pharmaceutical composition according to claim 16, wherein the method comprises treating atherosclerotic arteriosclerosis (AS) induced, aggravated, or accelerated by herpes virus infection.
  20. In paragraph 1, A compound that is 1-(2-(2-bromoethoxy)ethyl)-N-(4-cyanobenzyl)-6-((1-((1-hydroxy-2-methylpropane-2-yl)sulfonyl)cyclopropyl)methyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

Description

Antiviral pyrazolopyridinone compounds Related applications This application claims priority to U.S. Provisional Application No. 62/906,664 filed September 26, 2019, the contents of which are incorporated herein by reference. Technology field The present invention relates to novel bicyclic pyrazolopyridion compounds useful for treating herpes virus infections by inhibiting herpes virus replication. The compounds inhibit viral DNA polymerase of various herpes viruses, including cytomegalovirus (CMV) and herpes simplex virus. The present invention provides novel bicyclic pyrazolopyridion compounds as disclosed herein, pharmaceutical compositions containing such compounds, and methods for using these compounds and compositions in the treatment and prevention of herpes virus diseases. Human CMV, also known as human herpesvirus 5 (HHV-5), is a β-herpes virus that affects all populations worldwide, including adults and children with normal or compromised immune systems. While it is often asymptomatic in healthy individuals, CMV can be life-threatening in immunocompromised individuals. CMV is also a cause for concern during pregnancy, as it can infect the fetus from the mother and cause severe birth defects. There is no approved treatment to prevent or treat congenital CMV infection. In the transplant setting, current anti-CMV therapies include the nucleoside analogs valganciclovir (valGCV), ganciclovir (GCV), and cidofovir (CDV), and the pyrophosphate analog phoscarnet (FOS). Each of these therapeutic agents inhibits CMV DNA polymerase, a protein encoded by the UL54 gene, an enzyme essential for viral replication (References [PNAS 2003, 100(24), 14223-14228]; WO 2013/152063; WO 2005/012545). For solid organ transplant patients, primary treatment consists of prophylactic or preemptive therapy using GCV or the orally administered prodrug valGCV. GCV significantly reduces the risk of disease and can effectively treat active CMV infection. However, the aforementioned drugs exacerbate symptoms. GCV and valGCV can cause severe bone marrow suppression, which may place patients at risk of engraftment failure in stem cell transplant recipients. Secondary treatments such as CDV and FOS are associated with severe nephrotoxicity. Furthermore, resistance to current anti-CMV nucleoside analogs is a significant cause of treatment failure. Therefore, to provide safer CMV treatment and to combat herpes viruses resistant to known classes of antivirals, a new class of CMV therapeutics, particularly non-nucleoside compounds, is required. In addition to CMV, herpes viruses that cause widespread human viral infections include the Epstein-Barr virus (EBV), varicella zoster virus (VZV), and herpes simplex viruses HSV-1 and HSV-2. Other herpes viruses that cause disease in humans include human herpes simplex virus 6, human herpes simplex virus 7, and Kaposi's sarcoma-associated herpesvirus. Herpes virus infections are not only widespread but also persist for a lifetime in the host during the latent period. According to one estimate, more than 90% of adult humans are latently infected with at least one herpes virus that can reactivate after several years. For example, shingles occurs when the varicella-zoster virus (VZV) reactivates during the latent period, typically several years after the initial infection (chickenpox) has been controlled. Shingles is a painful condition that primarily affects the elderly and individuals with impaired immune function. Complications include post-herpetic neuralgia, a potentially debilitating chronic pain syndrome, to which anti-VZV inhibitors (nucleosides) have only a minimal effect. Immunocompromised individuals, such as transplant patients, are at high risk of reactivation of herpes viruses such as CMV, HSV, or VZV. Therefore, safe and potent antiviral agents with broad-spectrum herpes virus activity are of great importance. The present invention provides novel compounds that are active against several herpes viruses, including CMV, HSV, VZV, and EBV. The present invention provides a novel non-nucleoside compound that inhibits herpes virus DNA polymerase and possesses potent antiviral activity in vitro. The compound is active against several herpes viruses, including CMV, HSV, VZV, and EBV. Potent non-nucleoside polymerase inhibitors offer significant advantages over current anti-CMV agents. First, unlike nucleoside analogs, the compound is not incorporated by human polymerase and is therefore expected to have a higher safety profile than current anti-CMV drugs. Second, since the compound described herein exhibits activity against GCV-resistant viruses, it offers potential for rescue therapy in patients with cross-resistance to nucleoside analogs. Finally, the compound exhibits activity against several human herpes viruses, providing opportunities for extensive clinical use. The present invention also provides a pharmaceutical composition containing the novel compound, as well as a method of using the